David L. Paterson

100.3k total citations · 20 hit papers
586 papers, 61.6k citations indexed

About

David L. Paterson is a scholar working on Molecular Medicine, Epidemiology and Infectious Diseases. According to data from OpenAlex, David L. Paterson has authored 586 papers receiving a total of 61.6k indexed citations (citations by other indexed papers that have themselves been cited), including 285 papers in Molecular Medicine, 227 papers in Epidemiology and 173 papers in Infectious Diseases. Recurrent topics in David L. Paterson's work include Antibiotic Resistance in Bacteria (285 papers), Antibiotics Pharmacokinetics and Efficacy (150 papers) and Antibiotic Use and Resistance (117 papers). David L. Paterson is often cited by papers focused on Antibiotic Resistance in Bacteria (285 papers), Antibiotics Pharmacokinetics and Efficacy (150 papers) and Antibiotic Use and Resistance (117 papers). David L. Paterson collaborates with scholars based in Australia, United States and United Kingdom. David L. Paterson's co-authors include Robert A. Bonomo, Anton Y. Peleg, Harald Seifert, Louis B. Rice, Nina Singh, Gunnar Kahlmeter, Christian G. Giske, Patrick N. A. Harris, Yehuda Carmeli and Marc Struelens and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

David L. Paterson

566 papers receiving 59.8k citations

Hit Papers

Multidrug-resistant, extensively drug-resistant an... 2000 2026 2008 2017 2011 2000 2008 2005 2006 2.5k 5.0k 7.5k 10.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance
    2011 10.1k citations David L. Paterson, Louis B. Rice et al. profile →
  2. Adherence to Protease Inhibitor Therapy and Outcomes in Patients with HIV Infection
    2000 2.7k citations David L. Paterson et al. profile →
  3. Acinetobacter baumannii : Emergence of a Successful Pathogen
    2008 2.6k citations David L. Paterson et al. profile →
  4. Extended-Spectrum β-Lactamases: a Clinical Update
    2005 2.6k citations David L. Paterson, Robert A. Bonomo profile →
  5. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America Guidelines for Developing an Institutional Program to Enhance Antimicrobial Stewardship
    2006 2.5k citations David L. Paterson et al. Clinical Infectious Diseases profile →
  6. Antimicrobial Resistance in ESKAPE Pathogens
    2020 1.4k citations Brian M. Forde, Patrick N. A. Harris et al. profile →
  7. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections
    2006 1.1k citations David L. Paterson et al. profile →
  8. Resistance in Gram-Negative Bacteria: Enterobacteriaceae
    2006 700 citations David L. Paterson The American Journal of Medicine profile →
  9. Predictors of Mortality in Staphylococcus aureus Bacteremia
    2012 690 citations S. J. van Hal, David L. Paterson et al. profile →
  10. Escherichia coli O25b-ST131: a pandemic, multiresistant, community-associated strain
    2010 578 citations Hanna E. Sidjabat, David L. Paterson et al. profile →
  11. Population Pharmacokinetics of Colistin Methanesulfonate and Formed Colistin in Critically Ill Patients from a Multicenter Study Provide Dosing Suggestions for Various Categories of Patients
    2011 567 citations David L. Paterson, Fernanda P. Silveira et al. Antimicrobial Agents and Chemotherapy profile →
  12. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial
    2020 540 citations Yohei Doi, David L. Paterson et al. profile →
  13. Distribution ofLegionellaSpecies and Serogroups Isolated by Culture in Patients with Sporadic Community‐Acquired Legionellosis: An International Collaborative Survey
    2002 520 citations David L. Paterson et al. profile →
  14. Peritoneal Dialysis-Related Infections Recommendations: 2005 Update
    2005 507 citations David L. Paterson et al. profile →
  15. A Large Outbreak ofClostridium difficile–Associated Disease with an Unexpected Proportion of Deaths and Colectomies at a Teaching Hospital Following Increased Fluoroquinolone Use
    2005 507 citations A. William Pasculle, David L. Paterson et al. profile →
  16. Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae
    2017 479 citations Federico Pérez, Yohei Doi et al. Clinical Infectious Diseases profile →
  17. Systematic Review and Meta-Analysis of Vancomycin-Induced Nephrotoxicity Associated with Dosing Schedules That Maintain Troughs between 15 and 20 Milligrams per Liter
    2012 479 citations S. J. van Hal, David L. Paterson et al. Antimicrobial Agents and Chemotherapy profile →
  18. Treatment Outcome of Bacteremia Due to KPC-Producing Klebsiella pneumoniae: Superiority of Combination Antimicrobial Regimens
    2012 438 citations Zubair Qureshi, David L. Paterson et al. Antimicrobial Agents and Chemotherapy profile →
  19. Multidrug-Resistant Bacteria in the Community
    2016 423 citations David L. Paterson et al. profile →
  20. Global dissemination of a multidrug resistant Escherichia coli clone
    2014 422 citations Brian M. Forde, David L. Paterson et al. profile →

Peers

David L. Paterson
Comparison fields: 5 of 210
  • Molecular Medicine 31.1k
  • Epidemiology 19.2k
  • Infectious Diseases 15.2k
  • Pharmacology 13.3k
  • Endocrinology 11.2k
Replace Ronald N. Jones with:
Ronald N. Jones United States
Robert A. Bonomo United States
Yehuda Carmeli Israel
Patrice Nordmann France
David M. Livermore United Kingdom
Laurent Poirel France
Rafael Cantón Spain
Louis B. Rice United States
Fred C. Tenover United States
Christian G. Giske Sweden
Ronald N. Jones United States View profile →
Citations per field, relative to David L. Paterson
David L. Paterson · 1×
Citations per year, relative to David L. Paterson
David L. Paterson · 1×

Countries citing papers authored by David L. Paterson

Since Specialization
Citations

This map shows the geographic impact of David L. Paterson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David L. Paterson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David L. Paterson more than expected).

Fields of papers citing papers by David L. Paterson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David L. Paterson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David L. Paterson. The network helps show where David L. Paterson may publish in the future.

Co-authorship network of co-authors of David L. Paterson

This figure shows the co-authorship network connecting the top 25 collaborators of David L. Paterson. A scholar is included among the top collaborators of David L. Paterson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David L. Paterson. David L. Paterson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
# Work Indexed citations
1
Epidemiology and clinical significance of carbapenemases in Australia: a narrative review
2024 ·Internal Medicine Journal ·Abdullah Tarık Aslan, David L. Paterson
5
2
Trends in Enterobacterales Bloodstream Infections in Children
2024 ·PEDIATRICS ·(unknown), Kevin B. Laupland, Felicity Edwards, Weiping Ling, Samuel Channon‐Wells, David Harley, Kathleen Falster, David L. Paterson, Patrick N. A. Harris, Adam Irwin
1
3
Persistence of Detectable Pathogens by Culture-Independent Systems (T2 Magnetic Resonance) in Patients With Bloodstream Infection: Prognostic Role and Possible Clinical Implications
2023 ·Clinical Infectious Diseases ·Anna Maria Peri, Kevin O’Callaghan, (unknown), Bianca Graves, (unknown), (unknown), Karen Lim, (unknown), (unknown), Natalie Davidson, Alexis Tabah, Adam G. Stewart, Mark D. Chatfield, Patrick N. A. Harris, David L. Paterson
11
4
Significant clinical differences but not outcomes between Klebsiella aerogenes and Enterobacter cloacae bloodstream infections: a comparative cohort study
2023 ·Infection ·Kevin B. Laupland, Felicity Edwards, Patrick N. A. Harris, David L. Paterson
4
5
Bloodstream infections in neutropenic and non-neutropenic patients with haematological malignancies: epidemiological trends and clinical outcomes in Queensland, Australia over the last 20 years
2023 ·Clinical and Experimental Medicine ·Anna Maria Peri, Felicity Edwards, Andrea Henden, Patrick N. A. Harris, Mark D. Chatfield, David L. Paterson, Kevin B. Laupland
7
6
Bloodstream Infection and Colorectal Cancer Risk in Queensland Australia, 2000-2019
2023 ·The American Journal of Medicine ·Kevin B. Laupland, Felicity Edwards, Luis Furuya‐Kanamori, David L. Paterson, Patrick N. A. Harris
10
7
Clinical Implementation of Routine Whole-genome Sequencing for Hospital Infection Control of Multi-drug Resistant Pathogens
2022 ·Clinical Infectious Diseases ·Brian M. Forde, Haakon Bergh, (unknown), Krispin Hajkowicz, (unknown), E Geoffrey Playford, (unknown), Naomi Runnegar, Julia Clark, Amy V. Jennison, Susan Moss, Anna Hume, Hugo Leroux, Scott A. Beatson, David L. Paterson, Patrick N. A. Harris
47
8
Nafamostat Mesylate for Treatment of COVID-19 in Hospitalised Patients: A Structured, Narrative Review
2022 ·Clinical Pharmacokinetics ·(unknown), Steven Y. C. Tong, Justin T. Denholm, Gregory J. Dore, Asha C Bowen, Sharon R. Lewin, Balasubramanian Venkatesh, Thomas Hills, Zoe McQuilten, David L. Paterson, Susan C. Morpeth, Jason A. Roberts
17
9
Genomic surveillance, characterization and intervention of a polymicrobial multidrug-resistant outbreak in critical care
2021 ·Microbial Genomics ·Leah W. Roberts, Brian M. Forde, (unknown), Weiping Ling, Graeme R. Nimmo, Haakon Bergh, Narelle George, Krispin Hajkowicz, John F. McNamara, Jeffrey Lipman, (unknown), Mark A. Schembri, David L. Paterson, Scott A. Beatson, Patrick N. A. Harris
31
10
Burkholderia pseudomallei Clinical Isolates Are Highly Susceptible In Vitro to Cefiderocol, a Siderophore Cephalosporin
2020 ·Antimicrobial Agents and Chemotherapy ·(unknown), Gemma Robertson, Andrew Henderson, (unknown), Michelle J. Bauer, Kyra Cottrell, Ian Gassiep, Robert Norton, David L. Paterson, Patrick N. A. Harris
16
11
Genomic Investigation Reveals Contaminated Detergent as the Source of an Extended-Spectrum-β-Lactamase-Producing Klebsiella michiganensis Outbreak in a Neonatal Unit
2020 ·Journal of Clinical Microbiology ·(unknown), Brian M. Forde, Leah W. Roberts, Haakon Bergh, (unknown), Amy V. Jennison, Susan Moss, David L. Paterson, Scott A. Beatson, Patrick N. A. Harris
40
12
A protocol for a phase 3 multicentre randomised controlled trial of continuous versus intermittent β-lactam antibiotic infusion in critically ill patients with sepsis: BLING III
2019 ·Critical Care and Resuscitation ·Jeffrey Lipman, Stephen J. Brett, Jan J. De Waele, Menino Osbert Cotta, Joshua S. Davis, Simon Finfer, Parisa Glass, Serena Knowles, Shay McGuinness, John Myburgh, David L. Paterson, Sandra Peake, Dorrilyn Rajbhandari, Andrew Rhodes, Jason A. Roberts, Charudatt Shirwadkar, Therese Starr, Colman Taylor, Laurent Billot, Joel M. Dulhunty
35
13
Infections in Hematopoietic Cell Transplant Recipients: Results From the Organ Transplant Infection Project, a Multicenter, Prospective, Cohort Study
2017 ·Open Forum Infectious Diseases ·Mindy G. Schuster, Angela A. Cleveland, Erik R. Dubberke, Carol A. Kauffman, Robin K. Avery, Shahid Husain, David L. Paterson, Fernanda P. Silveira, Tom Chiller, Kaitlin Benedict, Kathleen M. Murphy, Peter G. Pappas
81
14
A Multicenter Randomized Trial of Continuous versus Intermittent β-Lactam Infusion in Severe Sepsis
2015 ·American Journal of Respiratory and Critical Care Medicine ·Joel M. Dulhunty, Jason A. Roberts, Joshua S. Davis, S. A. R. Webb, Rinaldo Bellomo, Charles D. Gomersall, Charudatt Shirwadkar, Glenn M. Eastwood, John Myburgh, David L. Paterson, Therese Starr, Sanjoy K. Paul, Jeffrey Lipman
167
15
A protocol for a multicentre randomised controlled trial of continuous beta-lactam infusion compared with intermittent beta-lactam dosing in critically ill patients with severe sepsis: the BLING II study
2013 ·Critical Care and Resuscitation ·Joel M. Dulhunty, Jason A. Roberts, Joshua S. Davis, S. A. R. Webb, Rinaldo Bellomo, Charles D. Gomersall, Charudatt Shirwadkar, Glenn M. Eastwood, John Myburgh, David L. Paterson, Therese Starr, Andrew Udy, Sanjoy K. Paul, Jeffrey Lipman
15
16
Treatment Outcome of Bacteremia Due to KPC-Producing Klebsiella pneumoniae: Superiority of Combination Antimicrobial Regimens breakdown →
2012 ·Antimicrobial Agents and Chemotherapy ·Zubair Qureshi, David L. Paterson, Brian A. Potoski, (unknown), (unknown), Emilia Mia Sordillo, Bruce Polsky, Jennifer Adams‐Haduch, Yohei Doi
438
17
Performance of Various Testing Methodologies for Detection of Heteroresistant Vancomycin-Intermediate Staphylococcus aureus in Bloodstream Isolates
2011 ·Journal of Clinical Microbiology ·S. J. van Hal, Michael C. Wehrhahn, (unknown), Joanne Mercer, Dehua Chen, David L. Paterson, Iain B. Gosbell
68
18
A survey of antibiotic prescribing practices in Australian and New Zealand intensive care units
2010 ·Critical Care and Resuscitation ·Joel M. Dulhunty, S. A. R. Webb, David L. Paterson, Rinaldo Bellomo, John Myburgh, Jason A. Roberts, Jeffrey Lipman
24
19
Presence of Plasmid-Mediated Quinolone Resistance in Klebsiella pneumoniae Isolates Possessing bla KPC in the United States
2008 ·Antimicrobial Agents and Chemotherapy ·Andrea Endimiani, Lenore L. Carias, Andrea M. Hujer, Christopher R. Bethel, Kristine M. Hujer, Federico Pérez, Rebecca A. Hutton, W. Fox, Geraldine S. Hall, Michael R. Jacobs, David L. Paterson, Louis B. Rice, Stephen G. Jenkins, Fred C. Tenover, Robert A. Bonomo
83
20
Simple Disk-Based Method for Detection of Klebsiella pneumoniae Carbapenemase-Type β-Lactamase by Use of a Boronic Acid Compound
2008 ·Journal of Clinical Microbiology ·Yohei Doi, Brian A. Potoski, Jennifer Adams‐Haduch, Hanna E. Sidjabat, A. William Pasculle, David L. Paterson
109

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ronald N. Jones Breakdown of academic impact, for papers by Robert A. Bonomo Breakdown of academic impact, for papers by Yehuda Carmeli Breakdown of academic impact, for papers by Patrice Nordmann Breakdown of academic impact, for papers by David M. Livermore Breakdown of academic impact, for papers by Laurent Poirel Breakdown of academic impact, for papers by Rafael Cantón Breakdown of academic impact, for papers by Louis B. Rice Breakdown of academic impact, for papers by Fred C. Tenover Breakdown of academic impact, for papers by Christian G. Giske
Rankless by CCL
2026